{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:00:33Z","timestamp":1789891233015,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,20]]},"DOI":"10.7759\/cureus.116568","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:04:01Z","timestamp":1789887841000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Obesity on Chemotherapy Pharmacokinetics, Toxicity, and Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia"],"prefix":"10.7759","author":[{"given":"Arun","family":"Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Graifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riddhi","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Varma","family":"CP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro L","year":"2024","unstructured":"Pagliaro L, Chen SJ, Herranz D, et al.. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024, 10:41. 10.1038\/s41572-024-00525-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0801","article-title":"Is there etiologic heterogeneity between subtypes of childhood acute lymphoblastic leukemia? A review of variation in risk by subtype","volume":"28","author":"Williams LA","year":"2019","unstructured":"Williams LA, Yang JJ, Hirsch BA, Marcotte EL, Spector LG. Is there etiologic heterogeneity between subtypes of childhood acute lymphoblastic leukemia? A review of variation in risk by subtype. Cancer Epidemiol Biomarkers Prev. 2019, 28:846-56. 10.1158\/1055-9965.EPI-18-0801","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba H","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020, 105:2524-39. 10.3324\/haematol.2020.247031","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000359","article-title":"Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy","volume":"2022","author":"Kotecha RS","year":"2022","unstructured":"Kotecha RS. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy. Hematology Am Soc Hematol Educ Program. 2022, 2022:611-7. 10.1182\/hematology.2022000359","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020382","article-title":"Environmental risk factors for childhood acute lymphoblastic leukemia: an umbrella review","volume":"14","author":"Onyije FM","year":"2022","unstructured":"Onyije FM, Olsson A, Baaken D, Erdmann F, Stanulla M, Wollschl\u00e4ger D, Sch\u00fcz J. Environmental risk factors for childhood acute lymphoblastic leukemia: an umbrella review. Cancers (Basel). 2022, 14:382. 10.3390\/cancers14020382","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040723","article-title":"Treatment of pediatric acute lymphoblastic leukemia: a historical perspective","volume":"16","author":"Hayashi H","year":"2024","unstructured":"Hayashi H, Makimoto A, Yuza Y. Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers (Basel). 2024, 16:723. 10.3390\/cancers16040723","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/03014460.2020.1808065","article-title":"A method for calculating BMI z-scores and percentiles above the 95th percentile of the CDC growth charts","volume":"47","author":"Wei R","year":"2020","unstructured":"Wei R, Ogden CL, Parsons VL, Freedman DS, Hales CM. A method for calculating BMI z-scores and percentiles above the 95th percentile of the CDC growth charts. Ann Hum Biol. 2020, 47:514-21. 10.1080\/03014460.2020.1808065","journal-title":"Ann Hum Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.818726","article-title":"Characterizing pharmacokinetics in children with obesity\u2014physiological, drug, patient, and methodological considerations","volume":"13","author":"Gerhart JG","year":"2022","unstructured":"Gerhart JG, Balevic S, Sinha J, Perrin EM, Wang J, Edginton AN, Gonzalez D. Characterizing pharmacokinetics in children with obesity\u2014physiological, drug, patient, and methodological considerations. Front Pharmacol. 2022, 13:818726. 10.3389\/fphar.2022.818726","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00352-8","article-title":"Drug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children","volume":"21","author":"Kyler KE","year":"2019","unstructured":"Kyler KE, Wagner J, Hosey-Cojocari C, Watt K, Shakhnovich V. Drug dose selection in pediatric obesity: available information for the most commonly prescribed drugs to children. Paediatr Drugs. 2019, 21:357-69. 10.1007\/s40272-019-00352-8","journal-title":"Paediatr Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017, 390:2627-42. 10.1016\/S0140-6736(17)32129-3","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000524261","article-title":"Prevalence of childhood obesity in the United States in 1999-2018: a 20-year analysis","volume":"15","author":"Tsoi MF","year":"2022","unstructured":"Tsoi MF, Li HL, Feng Q, Cheung CL, Cheung TT, Cheung BM. Prevalence of childhood obesity in the United States in 1999-2018: a 20-year analysis. Obes Facts. 2022, 15:560-9. 10.1159\/000524261","journal-title":"Obes Facts"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta S","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, et al.. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025, 392:875-91. 10.1056\/NEJMoa2411680","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore KP","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, et al.. Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020, 38:3282-93. 10.1200\/JCO.20.00256","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey DT","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL, et al.. Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022, 40:2106-18. 10.1200\/JCO.21.02678","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.001","article-title":"Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance","volume":"164","author":"Nijstad AL","year":"2022","unstructured":"Nijstad AL, Barnett S, Lalmohamed A, et al.. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. Eur J Cancer. 2022, 164:137-54. 10.1016\/j.ejca.2021.11.001","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12453","article-title":"Physiologically based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition","volume":"8","author":"Lee CM","year":"2019","unstructured":"Lee CM, Zane NR, Veal G, Thakker DR. Physiologically based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition. CPT Pharmacometrics Syst Pharmacol. 2019, 8:759-68. 10.1002\/psp4.12453","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001220","article-title":"Vincristine-associated neuropathy with antifungal usage: a Kaiser Northern California experience","volume":"40","author":"Nikanjam M","year":"2018","unstructured":"Nikanjam M, Sun A, Albers M, et al.. Vincristine-associated neuropathy with antifungal usage: a Kaiser Northern California experience. J Pediatr Hematol Oncol. 2018, 40:e273-7. 10.1097\/MPH.0000000000001220","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17572","article-title":"Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response","volume":"194","author":"Sassen SD","year":"2021","unstructured":"Sassen SD, Math\u00f4t RA, Pieters R, et al.. Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. Br J Haematol. 2021, 194:423-32. 10.1111\/bjh.17572","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"M\u00f6ricke A","year":"2016","unstructured":"M\u00f6ricke A, Zimmermann M, Valsecchi MG, et al.. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016, 127:2101-12. 10.1182\/blood-2015-09-670729","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese L","year":"2022","unstructured":"Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma. Front Pediatr. 2022, 10:902117. 10.3389\/fped.2022.902117","journal-title":"Front Pediatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0451-y","article-title":"Towards a model-based dose recommendation for doxorubicin in children","volume":"56","author":"V\u00f6ller S","year":"2017","unstructured":"V\u00f6ller S, Hempel G, W\u00fcrthwein G, et al.. Towards a model-based dose recommendation for doxorubicin in children. Clin Pharmacokinet. 2017, 56:215-23. 10.1007\/s40262-016-0451-y","journal-title":"Clin Pharmacokinet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701452","article-title":"Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Gao X","year":"2021","unstructured":"Gao X, Qian XW, Zhu XH, et al.. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia. Front Pharmacol. 2021, 12:701452. 10.3389\/fphar.2021.701452","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3508","article-title":"NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity","volume":"48","author":"Moriyama T","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, et al.. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016, 48:367-73. 10.1038\/ng.3508","journal-title":"Nat Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling MV","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M, et al.. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019, 105:1095-105. 10.1002\/cpt.1304","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01203-7","article-title":"Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia","volume":"35","author":"Stanulla M","year":"2021","unstructured":"Stanulla M, Schaeffeler E, M\u00f6ricke A, et al.. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia. 2021, 35:2650-7. 10.1038\/s41375-021-01203-7","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030272","article-title":"Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population","volume":"14","author":"Barnett S","year":"2021","unstructured":"Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population. Pharmaceuticals (Basel). 2021, 14:272. 10.3390\/ph14030272","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia R","year":"2021","unstructured":"Di Francia R, Crisci S, De Monaco A, et al.. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers. Cancers (Basel). 2021, 13:966. 10.3390\/cancers13050966","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00823-8","article-title":"Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies","volume":"59","author":"Clements JD","year":"2020","unstructured":"Clements JD, Zhu M, Kuchimanchi M, Terminello B, Doshi S. Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies. Clin Pharmacokinet. 2020, 59:463-74. 10.1007\/s40262-019-00823-8","journal-title":"Clin Pharmacokinet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot P","year":"2022","unstructured":"Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022, 47:1337-51. 10.1111\/jcpt.13741","journal-title":"J Clin Pharm Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia TM","year":"2017","unstructured":"Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017, 10:1-8. 10.1080\/17474086.2017.1262757","journal-title":"Expert Rev Hematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.906","article-title":"Population pharmacokinetic analysis of bortezomib in pediatric leukemia patients: model-based support for body surface area-based dosing over the 2- to 16-year age range","volume":"57","author":"Hanley MJ","year":"2017","unstructured":"Hanley MJ, Mould DR, Taylor TJ, et al.. Population pharmacokinetic analysis of bortezomib in pediatric leukemia patients: model-based support for body surface area-based dosing over the 2- to 16-year age range. J Clin Pharmacol. 2017, 57:1183-93. 10.1002\/jcph.906","journal-title":"J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13450","article-title":"Obesity-related glomerulopathy: current approaches and future perspectives","volume":"23","author":"Mart\u00ednez-Montoro JI","year":"2022","unstructured":"Mart\u00ednez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ, Fern\u00e1ndez-Garc\u00eda JC. Obesity-related glomerulopathy: current approaches and future perspectives. Obes Rev. 2022, 23:e13450. 10.1111\/obr.13450","journal-title":"Obes Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.077644","article-title":"Pediatric cytochrome P450 activity alterations in nonalcoholic steatohepatitis","volume":"45","author":"Li H","year":"2017","unstructured":"Li H, Canet MJ, Clarke JD, et al.. Pediatric cytochrome P450 activity alterations in nonalcoholic steatohepatitis. Drug Metab Dispos. 2017, 45:1317-25. 10.1124\/dmd.117.077644","journal-title":"Drug Metab Dispos"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001604","article-title":"Obesity as a potential risk factor for vincristine-induced peripheral neuropathy","volume":"42","author":"Sajdyk TJ","year":"2020","unstructured":"Sajdyk TJ, Boyle FA, Foran KS, et al.. Obesity as a potential risk factor for vincristine-induced peripheral neuropathy. J Pediatr Hematol Oncol. 2020, 42:e637-40. 10.1097\/MPH.0000000000001604","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1799","article-title":"Effect of body fat on population pharmacokinetics of high-dose methotrexate in pediatric patients with acute lymphoblastic leukemia","volume":"61","author":"Orgel E","year":"2021","unstructured":"Orgel E, Nabais T, Douglas C, Mittelman SD, Neely M. Effect of body fat on population pharmacokinetics of high-dose methotrexate in pediatric patients with acute lymphoblastic leukemia. J Clin Pharmacol. 2021, 61:755-62. 10.1002\/jcph.1799","journal-title":"J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285788","article-title":"Changes in asparaginase exposure and toxicity profiles in obese pediatric acute lymphoblastic leukemia patients","volume":"110","author":"Panetta JC","year":"2025","unstructured":"Panetta JC, Ashcraft E, Jeha S, et al.. Changes in asparaginase exposure and toxicity profiles in obese pediatric acute lymphoblastic leukemia patients. Haematologica. 2025, 110:1849-53. 10.3324\/haematol.2024.285788","journal-title":"Haematologica"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34529","article-title":"Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: a\u00a0Children's Oncology Group report","volume":"129","author":"Wadhwa A","year":"2023","unstructured":"Wadhwa A, Chen Y, Hageman L, et al.. Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: a\u00a0Children's Oncology Group report. Cancer. 2023, 129:151-60. 10.1002\/cncr.34529","journal-title":"Cancer"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton CC","year":"2018","unstructured":"Denton CC, Rawlins YA, Oberley MJ, Bhojwani D, Orgel E. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018, 65:e26891. 10.1002\/pbc.26891","journal-title":"Pediatr Blood Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28063","article-title":"Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia","volume":"67","author":"Hashmi SK","year":"2020","unstructured":"Hashmi SK, Navai SA, Chambers TM, Scheurer ME, Hicks MJ, Rau RE, Gramatges MM. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020, 67:e28063. 10.1002\/pbc.28063","journal-title":"Pediatr Blood Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.9952","article-title":"Overweight or obesity and outcomes in children with acute lymphoblastic leukemia","volume":"8","author":"Ladas EJ","year":"2025","unstructured":"Ladas EJ, Sheng H, Athale UH, et al.. Overweight or obesity and outcomes in children with acute lymphoblastic leukemia. JAMA Netw Open. 2025, 8:e259952. 10.1001\/jamanetworkopen.2025.9952","journal-title":"JAMA Netw Open"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03023-3","article-title":"Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network","volume":"133","author":"Lovell AL","year":"2025","unstructured":"Lovell AL, Makamo N, Veal GJ, et al.. Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network. Br J Cancer. 2025, 133:275-85. 10.1038\/s41416-025-03023-3","journal-title":"Br J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/532342-impact-of-obesity-on-chemotherapy-pharmacokinetics-toxicity-and-survival-outcomes-in-pediatric-acute-lymphoblastic-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:04:02Z","timestamp":1789887842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/532342-impact-of-obesity-on-chemotherapy-pharmacokinetics-toxicity-and-survival-outcomes-in-pediatric-acute-lymphoblastic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.116568","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}